Mapatumumab Biosimilar – Anti-TNFRSF10A, CD261 mAb – Research Grade

Introduction

Mapatumumab Biosimilar, also known as Anti-TNFRSF10A or CD261 mAb, is a monoclonal antibody that targets the TNF-related apoptosis-inducing ligand (TRAIL) receptor 1, also known as death receptor 4 (DR4). This biosimilar is a research grade version of the original Mapatumumab, which is a therapeutic antibody used for the treatment of various types of cancer.

Structure of Mapatumumab Biosimilar

Mapatumumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for binding to the TNFRSF10A receptor, while the constant region is responsible for mediating effector functions.

Mechanism of Action

The main target of Mapatumumab Biosimilar is the TNFRSF10A receptor, which is expressed on the surface of cancer cells. When the antibody binds to this receptor, it induces apoptosis (cell death) through the activation of the caspase cascade. This leads to the elimination of cancer cells and inhibits tumor growth.

Application of Mapatumumab Biosimilar

Mapatumumab Biosimilar has shown promising results in preclinical studies and has been evaluated in clinical trials for the treatment of various types of cancer, including lung, prostate, breast, and pancreatic cancer. It has also been used in combination with other cancer treatments, such as chemotherapy and radiation therapy, to enhance its effectiveness.

Advantages of Mapatumumab Biosimilar

Compared to the original Mapatumumab, the biosimilar version offers several advantages. First, it is less expensive, making it more accessible for research purposes. Second, as a biosimilar, it has a similar structure and mechanism of action as the original drug, ensuring its effectiveness. Lastly, it has a lower risk of adverse effects, as it is designed to target cancer cells specifically and does not affect healthy cells.

Future Potential

Mapatumumab Biosimilar has shown promising results in clinical trials and has the potential to become a valuable addition to the current treatments for cancer. It is also being studied for its potential use in other diseases, such as autoimmune disorders and infectious diseases. Further research and development are needed to fully understand the potential of this biosimilar.

Conclusion

In summary, Mapatumumab Biosimilar is a research grade monoclonal antibody that targets the TNFRSF10A receptor and induces apoptosis in cancer cells. Its structure, mechanism of action, and potential applications make it a promising candidate for the treatment of various types of cancer. With ongoing research and development, this biosimilar has the potential to improve the outcomes of cancer treatment and benefit patients worldwide.

Keywords

antibody, therapeutic target, Mapatumumab Biosimilar, Anti-TNFRSF10A, CD261 mAb, monoclonal antibody, TNF-related apoptosis-inducing ligand, TRAIL receptor 1, death receptor 4, cancer, apoptosis, caspase cascade, preclinical studies, clinical trials, lung cancer, prostate cancer, breast cancer, pancreatic cancer, chemotherapy, radiation therapy, biosimilar, adverse effects, autoimmune disorders, infectious diseases, research and development.